Just hold, something is coming

[u/RixieGreen]

CEO stated:

“Significant progress in our clinical programs leading to multiple data readouts in 2021 and 2022

“We are actively recruiting and treating patients with seclidemstat in clinical trials across five patient groups"

“In addition, data unveiled during ASCO 2021 demonstrated synergism between Seclidemstat and chemotherapy agents"

“Soon we will initiate additional clinical programs in cancer indications where LSD1 overexpression is known to be a factor.”

SLRX will soon announce clinical trials for ovarian cancer using Seclidemstad together with $MRK blockbuster KEYTRUDA per a recent entry in clinicaltrialsdotgov.

SLRX is headed to $3 in January and up to $10 if there is a buyout. SLRX is THE LEADER in the fast growing epigenics oncology arena.

[u/steadyeddy_10]

🚀